Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Midomafetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Midomafetamine SCHEMBL24088997 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL30064471 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL15162286 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL29353930 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL44210 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL2414825 | 0.98 | TAAR1 (0.97) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL25233404 | 0.98 | TAAR1 (0.97) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL25233250 | 0.98 | TAAR1 (0.97) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL31158474 | 0.97 | TAAR1 (0.94) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Midomafetamine SCHEMBL2421248 | 0.97 | TAAR1 (0.94) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137563-A1 | R(-)-MDMA COMPOSITIONS AND METHODS OF TREATMENT | EMPATHBIO, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| CN-119998433-A | Method for producing R-MDMA | 思维医学股份有限公司 | 2025-05-13 | — | — | CN | claimed |
| US-20240010628-A1 | METHODS OF MANUFACTURE OF R-MDMA | Mind Medicine, Inc. (US) | 2024-01-11 | — | — | US | claimed |
| US-12577222-B2 | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | TERRAN BIOSCIENCES INC. (US) | 2026-03-17 | — | — | US | disclosed |
| WO-2025137563-A1 | R(-)-MDMA COMPOSITIONS AND METHODS OF TREATMENT | EMPATHBIO, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | MINDSTATE DESIGN LABS INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250170095-A1 | COMPOSITIONS COMPRISING NON-RACEMIC MIXTURES OF (R)- AND (S)-3,4-METHYLENEDIOXYMETHAMPHETAMINE OR (R) AND (S) N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE AND USES THEREOF | PHARMALA BIOTECH INC. (CA) | 2025-05-29 | — | — | US | disclosed |
| CN-119998433-A | Method for producing R-MDMA | 思维医学股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| EP-3710837-B1 | CATHINONE TEST | UNIV SYDNEY TECHNOLOGY (AU) | 2025-05-07 | — | — | EP | disclosed |
| CN-119497589-A | Therapeutic combinations, compositions and methods for designing and producing conditions that promote mental well-being | 心境设计实验室股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| JP-2025502054-A | — | ユニヴェルシテートスピタル バーゼル | 2025-01-24 | — | — | JP | disclosed |
| WO-2022232948-A1 | PROCESSES FOR THE PREPARATION OF THE ENANTIOMERS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) AND N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE (MBDB) | PHARMALA BIOTECH INC. (CA) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022232949-A1 | PROCESSES FOR THE PREPARATION OF THE ENANTIOMERS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) AND N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE (MBDB) | PHARMALA BIOTECH INC. (CA) | 2022-11-10 | — | — | WO | disclosed |
| US-9403755-B2 | Isometheptene isomer | TONIX PHARMA HOLDINGS LIMITED (BERMUDA) (BM) | 2016-08-02 | — | — | US | disclosed |
| US-20140212486-A1 | ISOMETHEPTENE ISOMER | TONIX PHARMACEUTICALS INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8793078-B2 | Method for predicting activation energy using atomic fingerprint descriptor or atomic descriptor | BIOINFORMATICS & MOLECULAR DESIGN RESEARCH CENTER (KR) | 2014-07-29 | — | — | US | disclosed |
| US-20120084012-A1 | METHOD FOR PREDICTING ACTIVATION ENERGY USING ATOMIC FINGERPRINT DESCRIPTOR OR ATOMIC DESCRIPTOR | BIOINFORMATICS & MOLECULAR DESIGN RESEARCH CENTER (KR) | 2012-04-05 | — | — | US | disclosed |
| US-20110213558-A1 | METHOD FOR PREDICTING ACTIVATION ENERGY USING AN ATOMIC FINGERPRINT DESCRIPTOR OR AN ATOMIC DESCRIPTOR | BIOINFORMATICS & MOLECULAR DESIGN RESEARCH CENTER (KR) | 2011-09-01 | — | — | US | disclosed |
| EP-2354987-A2 | METHOD FOR PREDICTING ACTIVATION ENERGY USING AN ATOMIC FINGERPRINT DESCRIPTOR OR AN ATOMIC DESCRIPTOR | Bioinformatics&Molecular Design Research Center (KR) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010056053-A2 | METHOD FOR PREDICTING ACTIVATION ENERGY USING AN ATOMIC FINGERPRINT DESCRIPTOR OR AN ATOMIC DESCRIPTOR | 사단법인 분자설계연구소 (KR) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577222-B2 | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | DRD2, DRD1, DRD3 | SLC6A4 59/4885SLC6A2 17/4885SLC6A3 5/4885 |
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | CNR2, CNR1, HTR6 | SLC6A4 84/4885SLC6A2 410/4885SLC6A3 125/4885 |
| US-20140212486-A1 | ISOMETHEPTENE ISOMER | HRH1, OPRM1, AGTR1 | SLC6A4 84/4885SLC6A2 113/4885SLC6A3 111/4885 |
| US-20250170095-A1 | COMPOSITIONS COMPRISING NON-RACEMIC MIXTURES OF (R)- AND (S)-3,4-METHYLENEDIOXYMETHAMPHETAMINE OR (R) AND (S) N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE AND USES THEREOF | DRD3, DRD1, DRD2 | SLC6A4 28/4885SLC6A2 32/4885SLC6A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.